A dose-finding study of nanoparticle albumin-bound paclitaxel plus cisplatin in patients with metastatic nasophyngeal carcinomas

Journal of Clinical Oncology, 2017.

Cited by: 0|Bibtex|Views3|

Abstract:

6049 Background: Nanoparticle albumin-bound paclitaxel (Abraxane, ABX), is a novel formulation of paclitaxel that has proved superior efficacy compared with conventional paclitaxel in the treatment of several metastatic cancers. We undertook this trial to determine the optimal dose and to preliminarily aseess efficacy of ABX plus cisplati...More

Code:

Data:

Your rating :
0

 

Tags
Comments